In UA/NSTEMI patients with high-risk features (eg, elevated troponin level) treated with UFH and ade- quately pretreated with clopidogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban).616,619 (Level of Evidence: B) SIHD Class IIa 1. In patients undergoing elective PCI treated with UFH and not pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban).619 621 (Level of Evidence: B) Class IIb 1. In patients undergoing elective PCI with stent im- plantation treated with UFH and adequately pre- treated with clopidogrel, it might be reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tiro- fiban).619,622 624 (Level of Evidence: B) See Online Data Supplement 24 for additional data regarding IV antiplatelet therapy. In the era before DAPT, trials of adequately dosed GP IIb/IIIa inhibitors in patients undergoing balloon angioplasty and coronary stent implantation demonstrated a reduction in the incidence of composite ischemic events with GP IIb/IIIa treatment, primarily through a reduction of enzymatically defined MI.613,615,618,620,621 Earlier RCTs of GP IIb/IIIa inhib- itors were generally conducted in patients treated with UFH. In some trials, use of GP IIb/IIIa inhibitors are associated with some increased bleeding risk, and trials of these agents have generally excluded patients at high risk of bleeding (eg, tions about use of GP IIb/IIIa inhibitors are best construed as applying to those patients not at high risk of bleeding complications. 